Table 5 Thromboembolic events according to Cisplatin-based chemotherapy regimen
Chemotherapy Regimen | Patients | Thromboembolic Events | p-value | ||
|---|---|---|---|---|---|
(n) | (%) | (n) | (%) | ||
Cisplatin-Docetaxel-5FU | |||||
Head and Neck | 95 | 38.8 | 0 | 0 | <0.0001 |
Gastric | 136 | 55.5 | 28 | 20.6 | |
Esophageal | 7 | 2.9 | 3 | 42.9 | |
Others | 7 | 2.9 | 0 | 0 | |
Total | 245 | 31 | 12.7 | ||
Cisplatin-XRT | |||||
Cervical | 101 | 33.8 | 7 | 6.9 | 0.2166 |
Head and Neck | 184 | 61.5 | 5 | 2.7 | |
Others | 14 | 4.7 | 1 | 7.1 | |
Total | 299 | 13 | 4.3 | ||
Cisplatin-Docetaxel | |||||
Lung | 181 | 93.3 | 12 | 6.6 | 0.9999 |
Others | 13 | 6.7 | 1 | 7.7 | |
Total | 194 | 13 | 6.7 | ||